


Provided for non-commercial research and education use.

Not for reproduction, distribution or commercial use.



Egyptian Academic Journal of Biological Sciences is the official English language journal of the Egyptian Society for Biological Sciences, Department of Entomology, Faculty of Sciences Ain Shams University.

Physiology & molecular biology journal is one of the series issued twice by the Egyptian Academic Journal of Biological Sciences, and is devoted to publication of original papers that elucidate important biological, chemical, or physical mechanisms of broad physiological significance.

www.eajbs.eg.net



Protective Effects of Zinc Chloride on Cyclophosphamide-Induced Genotoxicity in Male Albino Rat Tissues *in vivo*

Fayza M. Aly

Zoology Department, Faculty of Science, South Valley University, Qena, 83523, Egypt

E.Mail : fayzamosstafa2000@yahoo.com

ARTICLE INFO

Article History

Received: 25/8/2017

Accepted: 29/9/2017

Keywords:

cyclophosphamide, Zinc chloride, DNA damage, chromosomal aberrations and mitotic index.

ABSTRACT

The aim of this study was to assess the potential protective effect of zinc chloride ($ZnCl_2$) as an antioxidant against the cytotoxic and mutagenic effects induced by cyclophosphamide (chemotherapeutic agent), using mutagenicity tests; molecular assay, chromosomal aberrations (CA), and Mitotic index (MI) *in vivo* as the biomarkers. The experiment was designed as four groups (6 rats per group). Group 1 was injected intraperitoneally (i.p.) with saline solution (1 ml/kg body weight) every other day for 20 days and served as (control group). Group 2 (the treated group) was injected i.p. with a single dose of CP (200 mg/kg b. w.). Group 3 was injected i.p. with a single dose of CP (200 mg/kg b. w.) and treated simultaneous by $ZnCl_2$ (4 mg/kg b. w.) every other day for 20 days, while group 4 (the protective group) was pretreated with $ZnCl_2$ (4 mg/kg b. w.) every other day for 20 days, then treated with a single dose of CP (200 mg/kg b. w.) on the 21st day and was left. The experiment extended for 45 days after the treatment with the cyclophosphamide dose. The results revealed changes in the number, position, and intensity of DNA fragments for liver and kidney tissues in the treated rats with cyclophosphamide, in addition to significant decline in mitotic index and increase in the frequency of chromosomal aberrations compared with the control group. These results may be attributed to the fact that cyclophosphamide can induce genotoxicity through DNA damage in healthy cells. In comparison, rats that were treated simultaneous and pretreated with zinc chloride and then treated with a single dose of cyclophosphamide showed marked improvement in DNA fragments, decrease in the frequency of chromosomal aberration, and an elevation in mitotic index. Furthermore, pretreatment with zinc chloride revealed more protective role in mitotic index and reduce markedly DNA damage and chromosomal aberrations that induced by cyclophosphamide than those showed with the treatment with zinc chloride simultaneousity with Cp treatment. Pretreatment of Zinc chloride may open an interesting field concerning its possible use in medicine applications, as a protective treatment to reduce the side effects that can occur by cyclophosphamide treatment and other chemotherapeutic agents.

INTRODUCTION

Cyclophosphamide (CP) is an effective anti-cancer alkylating agent, on the other hand it possesses cytotoxic effects towards normal cells (Kim *et al.*, 2013). CP can destroy the normal antioxidant system by active metabolites represented in phosphoramidate mustard and acrolein resulting in the accumulation of reactive oxygen species, that can cause DNA damage. Several previous studies reported that cyclophosphamide has carcinogenic effects in healthy human and animal tissues (Rehman *et al.*, 2012), it causes gene mutations, chromosomal aberrations in mice tissues *in vivo* and *in vitro* test systems, and an elevated frequency of secondary treatment-related tumors in human cancer survivors (Ember *et al.*, 1995; Ridder *et al.*, 1998; Sundramoorthy *et al.*, 2004; Kruawanand *et al.*, 2006). Numerous studies using the Chromosome aberration (CA) and Mitotic index (MI) *in vivo* and *in vitro* as the biomarkers reported that treatment with cyclophosphamide can induce cytotoxic and mutagenic effects in bone marrow cells of rat and rabbit (Popov *et al.*, 2011; Sharma *et al.*, 2012; Sharma V. and Agrawal 2015; Sushma *et al.*, 2015; Koura *et al.*, 2017). Therefore, it is necessary to develop antioxidant materials to reduce the side effects of CP and the other chemotherapeutics.

Zinc is an essential metal that is integral to many enzymes and transcription factors in the cell. It plays an important role in protecting DNA and other cellular components from oxidation and damage through its participating in vital processes such as transcription and replication of DNA through zinc finger proteins (Levine, 1997; Powell, 2000; Prasad, 2003; Ho, 2004; Emily, 2004; Ebisch *et al.*, 2007; Leoni *et al.*, 2014). DNA transcription is a main part of germ cell development, therefore zinc is

affecting important biological processes such as cell division, growth, and differentiation; and it maintains DNA strand from damage (Badkoobeh *et al.*, 2013; Grüngreiff 2016).

Other studies (Satoh *et al.*, 1993; Sandstrom *et al.*, 1994; Lindahl *et al.*, 1998; Noh and Koh, 2000; Dhawan and Chadha, 2010; Maremanda, *et al.*, 2014) suggest that zinc has a role as an anticancer and its treatment increases resistance against the tumor in mice, thus it has a potential effect on apoptosis. Estibaliz *et al.*, (2003) reported that pretreatment with zinc showed modulation in DNA damage and gave results near the control levels. For this, in the present study, rats were exposed to ZnCl₂ pre and simultaneous treatment via intraperitoneal injection, followed by the injection with cyclophosphamide to evaluate the protective effects of ZnCl₂ on DNA fragments in liver and kidney tissues by using inter simple sequence repeat (ISSR) markers. To obtain more effective results, the author assessed the mitotic index and chromosome aberrations using bone marrow cells analysis of the tested rats.

MATERIALS AND METHODS

1- Chemical Materials:

Cyclophosphamide (CP):

Cyclophosphamide was supplied as vials from Baxter Oncology, Germany.

Zinc Chloride (ZnCl₂):

ZnCl₂ salt from El-Nasr Pharmaceutical Chemical Co.

Primers:

Five ISSR primers were used in the detection of polymorphism among the liver and kidney tissues of tested rat groups. These primers were synthesized by Metabion Corp Germany.

Experimental Animals:

Twenty four of male albino rats of approximate weight (20-25 g) were obtained from the animal house of Veterinary College, south valley

university. The rats were housed in the animal house of the science college, South Valley University, Qena, under normal conditions with a balanced diet and water *ad libitum* until the weight of rats reached of (200-250 g).

Experimental Design:

When the rats reached from 200 to 250 g, 24 rats were divided randomly into 4 groups of 6 rats each.

Group I: This group is (control group), each rat of this group was injected intraperitoneally with saline solution (0.9 % NaCl, 1 ml/kg b. w.) every other day for 20 days.

Group II: This group is (treated group), each rat of which was injected intraperitoneally by a single dose of CP (200 mg/kg b. w.) and was left for 45 days.

Group III: This group was treated with a single dose of CP simultaneous with the treatment with ZnCl₂ (treated group with CP+ZnCl₂), this group was injected intraperitoneally with a single dose of CP (200 mg/kg b. w.) followed by ZnCl₂ (4 mg/kg b. w., i.p.) every other day for 20 days and was left.

Group IV: This group is (protective group) that received i. p. ZnCl₂ (4 mg/kg b. w.) every other day for 20 days before a single dose of cyclophosphamide (200 mg/kg b. w.) on the 21st day and was left for 45 days.

The experiment extended for 45 days after the treatment with the cyclophosphamide dose in the tested rat groups, under normal conditions with a balanced diet and water *ad libitum*.

Molecular Studies:

a- DNA Extraction:

Three rats of each group were dissected to obtain DNA from liver and kidney tissues according to (Zietkiewicz *et al.*, 1994). DNA concentration was determined by diluting the DNA 1:5 in dH₂O. 10 µg of a DNA size marker (Lambda DNA digested with HindIII and Phi x 174 DNA digested with HaeIII).

This marker can cover from 310 bp to 23130 bp of DNA fragments size, and a range of concentration from 11 ng to 95 ng. Thus, estimation of the DNA concentration in a given sample was achieved by comparing the degree of fluorescence of the unknown DNA band with the different bands in the DNA size marker.

b- ISSR Reaction:

PCR amplification reactions were carried out as described by (Sharaf-Eldeen *et al.*, 2006). Reactions in PCR system were performed in 25 µl volume that composed of (1x reaction buffer, 0.2 mM of dNTPs, 1.5 mM MgCl₂, 0.2 µM of primer, 0.5 unit of Taq polymerase, and 50 ng of template DNA). The temperature profile in the different cycles was as follows: an initial strand separation cycle at 94°C for 5 min followed by 40 cycles comprised of a denaturation step at 94°C for 1 min, an annealing step at 45°C for 1 min, and an extension step at 72°C for 1.5 min. The final cycle was a polymerization cycle for 7 min at 72°C.

c- Electrophoresis Analysis:

PCR products were mixed with 5 µl gel loading dye and resolved by electrophoresis in a 1.5% agarose gel containing ethidium bromide (0.5 mg/ml) in 1 x TBE buffer at 120 volts. A 100 bp DNA ladder was used as molecular size standard. PCR products were visualized under UV light and documented using a TMXR+ Gel Documentation System (Bio-Rad).

Cytogenetic Studies:

a- Chromosomal Preparations:

After the end of the determined period of the experiment, three rats from each group were injected intraperitoneally with 0.05% colchicine, for 2.5 h. before sacrifice. Bone marrow preparations for the analysis of metaphase cells were obtained as described by Yosida *et al.*, (1977) with

some modifications. 200 metaphase spreads per tested group were screened to determine the number and types of chromosomal aberrations per group.

b- Statistical Analysis:

Number of chromosomal aberrations was expressed as means \pm SE. 200 metaphases were counted for three rats in each group. Statistical analysis of cytogenetic was performed on SPSS software (version 24). P values were less than 0.05 levels ($P < 0.05$) were considered to be significant.

c- Calculation of Mitotic Index:

Form mitotic division stages about 5000 cells counted for each animal. Mitotic index was calculated according to the formula that described by Singh and Sankhla (2010).

$$\text{Mitotic index} = A/A+B$$

Where A= No. of dividing bon marrow cells (metaphase)

B= No. of non dividing bon marrow cells

RESULTS

a-The Molecular Genetic Results:

Inter simple sequence repeats (ISSRs) analysis was performed to evaluate the protective effects of pre and simultaneous treatment with zinc chloride against Cyclophosphamide-induced genotoxicity in rat tissues. Farther, the comparison between the effect of pretreatment and the simultaneity treatment of zinc chloride on cyclophosphamide against its genotoxicity. Two tissues (liver and kidney) of male albino rats were used to obtain DNA. The results of each treated group were examined through inter simple sequence marker in comparison with the control group. Data were illustrated for five primers in (Figures 1 and 2). These primers that used consist of different di- and tri-nucleotide repeats to determine the genetic variation among the tested groups as well as possible (Table 1). The molecular size of amplified bands in liver and kidney were illustrated in (Table 2).

Table (1). The primers code and nucleotide sequences.

| Primer | Primer Sequence 5'-3' |
|---------|--------------------------|
| ISSR- 1 | 5'-ACACACACACACACACYA-3' |
| ISSR- 2 | 5'-AGAGAGAGAGAGAGAGYT-3' |
| ISSR- 3 | 5'-CTCCTCCTCCTCCTCTT-3' |
| ISSR- 4 | 5'-CTCTCTCTCTCTCTCTCG-3' |
| ISSR- 5 | 5'-TCTCTCTCTCTCTCTCA-3' |

nucleotide code: Adenine=A, Cytosine=C, Guanine=G, Thymine=T and Y=Cor T

The results from liver tissue: the five primers (primer ISSR-1, ISSR-2, ISSR-3, ISSR-4, and ISSR-5) were generated 11, 15, 14, 17, and 8 bands, respectively, with an average 13 bands per primer. The five primers developed a total of 209 bands in which 76 of them were polymorphic bands (36.4% polymorphism) as shown in (Figure 1). All the five primers produced polymorphic bands by different percentage, 36.4 %, 62.5 %, 64.3 %, 52.9%, and 25.0% polymorphism (primer

ISSR-1, ISSR-2, ISSR-3, ISSR-4, and ISSR-5), respectively (Table 3). The results showed also that all treated groups of rats had disappeared or appeared new bands compared with control group. Control group generated 57 ISSR bands with the five primers opposite to 43, 53, and 57 bands for groups 2, 3, and 4, respectively (Table 2). These results revealed that the number of lost bands in group 2 and 3 was obviously higher than the number of new bands compared with the control group. Animals treated with

cyclophosphamide (group 2) showed the highest lost bands (the total bands was 43 compared to 57 for control group). Thus, group 2 could be an obvious indication for the high genotoxic effect of cyclophosphamide due to losses of alleles compared with the groups that treated by cyclophosphamide plus zinc chloride, groups 3 (52 bands) and 4 (57 bands). Rats in group 3 and 4 with simultaneity and pretreatment with zinc Chloride every other day for 20 days respectively, and followed by treated with CP, showed improvement in DNA

strand and increase in bands number (52 and 57 bands, respectively) compared with group 2 (43 bands) that was treated with CP only. These results suggested that the animals treated with cyclophosphamide and received zinc chloride had less genotoxic effect than those treated with cyclophosphamide only, and zinc chloride pretreatment (group 4) exhibited more protective that lead to better result than simultaneity treatment in group 3 compared to the control.

Table 2. Number of obtained bands using five ISSR primers analysis in treated and control groups.

| Marker name | Total band Number | Mobility Range (bp) | Number of bands | | | | Mean of band Frequency \pm SE |
|------------------|-------------------|---------------------|-------------------------|----------------------|--|--|---------------------------------|
| | | | Group 1 (Control group) | Group 2 (CP treated) | Group 3 (CP+ZnCl ₂ treated) | Group 4 (CP+ znCl ₂ Pretreated) | |
| In liver | | | | | | | |
| ISSR-1 | 11 | 170-670 | 10 | 10 | 9 | 11 | 0.91 \pm 0.05 |
| ISSR-2 | 15 | 160-850 | 12 | 7 | 10 | 14 | 0.72 \pm 0.08 |
| ISSR-3 | 14 | 190-1000 | 13 | 8 | 10 | 10 | 0.75 \pm 0.07 |
| ISSR-4 | 17 | 260-1400 | 14 | 11 | 15 | 14 | 0.79 \pm 0.07 |
| ISSR-5 | 8 | 290-1000 | 8 | 7 | 8 | 8 | 0.97 \pm 0.03 |
| Sum | | | 57 | 43 | 52 | 57 | |
| In kidney | | | | | | | |
| ISSR-1 | 11 | 170-670 | 11 | 10 | 10 | 11 | 0.95 \pm 0.05 |
| ISSR-2 | 12 | 160-850 | 12 | 9 | 11 | 12 | 0.92 \pm 0.05 |
| ISSR-3 | 11 | 210-850 | 10 | 7 | 9 | 7 | 0.75 \pm 0.11 |
| ISSR-4 | 12 | 260-850 | 12 | 11 | 11 | 12 | 0.96 \pm 0.04 |
| ISSR-5 | 7 | 290-770 | 5 | 7 | 5 | 5 | 0.79 \pm 0.14 |
| Sum | | | 50 | 44 | 46 | 47 | |

Table 3. Detected polymorphism for ISSR marker in the tested rats compared to the control group.

| Marker Total | Total | Monomorphic Bans | Polymorphic Bands | Polymorphism (%) |
|------------------|-------|------------------|-------------------|------------------|
| In liver | | | | |
| ISSR-1 | 11 | 7 | 4 | 36.4 % |
| ISSR-2 | 15 | 5 | 10 | 33.3 % |
| ISSR-3 | 14 | 5 | 9 | 64.3 % |
| ISSR-4 | 17 | 8 | 9 | 52.9 % |
| ISSR-5 | 8 | 6 | 2 | 25.0 % |
| In kidney | | | | |
| ISSR-1 | 11 | 9 | 2 | 18.2 % |
| ISSR-2 | 12 | 8 | 4 | 33.3 % |
| ISSR-3 | 11 | 6 | 5 | 45.5 % |
| ISSR-4 | 12 | 10 | 2 | 20.0 % |
| ISSR-5 | 7 | 4 | 3 | 42.9 % |

The results from kidney tissue: these results indicate that kidney tissue showed less genotoxic effect compared to liver tissue with the treatment by cyclophosphamide. With the kidney tissues, the five primers generated 187 bands in which 38 of them were polymorphic bands (20.3% polymorphism) as shown in (Figure 2). All primers produced polymorphic bands with less percentage compared to liver tissue, 18.2 %, 33.3 %, 45.5 %, 20.0%, and 42.9 % (primer ISSR-1, ISSR-2, ISSR-3, ISSR-4, and ISSR-5), respectively (Table 3). Treated groups had disappeared or appeared new bands also compared with control group (Fig. 2). In control group, 50 ISSR bands were obtained opposite to 44, 46, and 47 bands for groups 2, 3, and 4, respectively (Table 2). Results revealed also, the lost bands in treated groups were more than the new generated bands compared with control group. Rats treated with cyclophosphamide (group 2) showed the highest lost bands (the total bands was 44 compared to 50 for control group), which could be an obvious indication for the genotoxic effect of cyclophosphamide in renal tissue due to losses of alleles. Rats in groups 3 and 4 that were treated with doses of zinc chloride every other day for 20 days simultaneously and pretreatment, respectively, and followed by a single dose of cyclophosphamide, showed increase in the number of bands (46 and 47) bands, respectively, compared with Cp treated group (44 bands). These results suggested that the rats treated with

zinc chloride and received cyclophosphamide showed less genotoxic effect in renal tissue than those treated with cyclophosphamide only.

Moreover, the present results showed that liver tissue is more sensitive to toxic actions for CP than kidney tissue. In group 2 (The treated group by cyclophosphamid) liver tissue generated 43 bands, 22 of them were polymorphic bands with percentage 51.2%, while kidney tissue generated 44 bands, 11 of them polymorphic bands with 25% percentage. These results of polymorphism were improved in liver tissue under the effect of zinc chloride to 11.5% and 10.5% in simultaneous and pretreatment treatment with CP (group 3 and 4), respectively. In kidney tissue, the results were improved to 10.9% and 6.4% in group 3 and 4, respectively (Table 4).

Overall, the present study demonstrated that both the pre and the simultaneous treatment with ZnCl₂ have a protective role against CP-induced genotoxicity in liver and kidney tissues. This protection was more effective in pretreated rat group with ZnCl₂ for 20 days before treated with CP compared to this treated simultaneously with ZnCl₂ and CP as shown in Figure 4 that demonstrated the relationships among tested rat groups and control group in liver and kidney tissues. Consequently, pretreatment with ZnCl₂ may be applied as a protective agent for people in need of treatment by cyclophosphamide.

Table 4. Detected polymorphism for ISSR primer in the three tested groups compared with control group.

| Primer | CP (group 2) | | | CP+ZnCl ₂ (group 3) | | | CP+preZnCl ₂ (Group 4) | | |
|------------------|--------------|------|-----------|--------------------------------|-------|-----------|-----------------------------------|-------|------------|
| | Total Number | Poly | Polymor % | Total Number | Poly. | Polymor % | Total Number | Poly. | Polymor. % |
| In liver | | | | | | | | | |
| ISSR-1 | 10 | 2 | 20 | 9 | 1 | 11.1 | 11 | 1 | 9.1 |
| ISSR-2 | 7 | 5 | 71.4 | 10 | 2 | 20 | 14 | 3 | 21.4 |
| ISSR-3 | 8 | 7 | 87.5 | 10 | 2 | 20 | 10 | 2 | 20 |
| ISSR-4 | 11 | 7 | 63.6 | 15 | 1 | 6.67 | 14 | 0 | 0 |
| ISSR-5 | 7 | 1 | 14.3 | 8 | 0 | 0 | 8 | 0 | 0 |
| Sum | 43 | 22 | 51.2 | 52 | 6 | 11.5 | 57 | 6 | 10.5 |
| In kidney | | | | | | | | | |
| ISSR-1 | 10 | 1 | 10 | 10 | 1 | 10 | 11 | 0 | 0 |
| ISSR-2 | 9 | 3 | 33.3 | 11 | 1 | 9.1 | 12 | 0 | 0 |
| ISSR-3 | 7 | 4 | 57.1 | 9 | 2 | 33.3 | 7 | 3 | 42.9 |
| ISSR-4 | 11 | 1 | 9.1 | 11 | 1 | 9.1 | 12 | 0 | 0 |
| ISSR-5 | 7 | 2 | 28.6 | 5 | 0 | 0 | 5 | 0 | 0 |
| Sum | 44 | 11 | 25 | 46 | 6 | 10.9 | 47 | 3 | 6.4 |

Poly= Polyploidy Polymor= polymorphism

b- Cytogenetic Results:

The antimutagenic potential of zinc chloride against cyclophosphamide genotoxicity was evaluated using *in vivo* assays of rat bone marrow cells. Doses of 4 mg/kg of zinc chloride every other day for 20 days was tested in pre and simultaneously treatment with a single dose of cyclophosphamide compared with the control group and treatment group with CP only. It was observed that in rats administered with cyclophosphamide there was a significant increase in the number of chromosomal aberrations and a decline in mitotic index as compared to the control group. In rats that simultaneous or pretreated with zinc chloride, and followed by administered cyclophosphamide, the number of chromosomal aberrations were less and the mitotic index was nearly equivalent to the control group (Table 5&6 and Figure 3). Table 5 illustrated the results of types and numbers of chromosomal aberrations in bone marrow cells of male albino rats that were injected with CP (200mg/kg b. w.). CP induced several

chromosomal aberrations in the tested rats, such as ring chromosomes, chromatid deletion, dicentric chromosomes, chromosomal fragment, end to end, and polyploidy that showed that the mean frequency of total chromosomal aberrations was significantly increased after CP treatment for 45 days (23 ± 3.86) when compared with control (0.67 ± 0.33). The treated rats with CP simultaneously plus ZnCl₂ treatment or pretreatment with ZnCl₂ exhibited significant reduction in chromosomal aberrations induced by CP (10.5 ± 2.23 and 5.67 ± 1.41), respectively. Pretreatment of zinc chloride before treatment with cyclophosphamide showed more effective result in chromosomal aberrations than those that concurrently treatments with ZnCl₂ and CP (5.67 ± 1.41 opposite 10.5 ± 2.23), respectively, and pretreatment of zinc chloride before treatment with cyclophosphamide showed mitotic index nearly equivalent to the control group (0.019 opposite 0.020), respectively, (Table 6).

Table 5. Chromosomal aberrations in rat bone marrow cells after treatment with CP, CP+ ZnCl₂ and ZnCl₂ pretreatment +CP.

| Group | Chromosomal aberrations | | | | | | Total number of aberrations | Average number of aberrations |
|------------------------------------|-------------------------|----|----|----|----|-------|-----------------------------|-------------------------------|
| | R | D | EE | Dc | F | Poly. | | |
| Control (Group 1) | 1 | 2 | 0 | 0 | 0 | 1 | 4 | 0.67 ±0.33 |
| CP group(Group2) | 35 | 30 | 10 | 25 | 24 | 14 | 138 | 23±3.86* |
| CP+ ZnCl ₂ sim. Group 3 | 18 | 14 | 4 | 13 | 9 | 5 | 63 | 10.5 ±2.23* |
| ZnCl ₂ pre.+ CP Group 4 | 9 | 8 | 0 | 7 | 7 | 3 | 34 | 5.67 ±1.41* |

Sim= simultaneously treatment, pre.= pretreatment

R=chromosomal ring, D= chromatide deletions, EE= end to end, Dc= dicentric chromosome, F= chromosomal fragments and Poly.= polyploidy.

*Significant compared to control at P< 0.05

Table 6: Protective effect of zinc chloride against cyclophosphamide induced decline in mitotic index.

| Dose | No. of dividing cells (A) | No. of non dividing cells (B) | Total cells | Mitotic index (MI) |
|------------------------------------|---------------------------|-------------------------------|-------------|--------------------|
| Control (Group 1) | 100 | 4900 | 5000 | 0.020 |
| CP group (Group2) | 59 | 4940 | 5000 | 0.012 |
| CP+ ZnCl ₂ sim. Group 3 | 83 | 4917 | 5000 | 0.017 |
| ZnCl ₂ pre.+ CP Group 4 | 94 | 4906 | 5000 | 0.019 |

DISCUSSION

Cyclophosphamide is a chemotherapeutic agent that is widely used as anticancer. Such as most chemotherapeutic agents, it does not distinguish between normal and cancerous cells, so it kills normal cells as well. Acrolein and phosphoramidate are active compounds of CP, in spite of these compounds, reduce the growth of cancerous cells by acting at DNA level (Haubitz, 2007). It induce a variety of changes in DNA, that can cause secondary tumors in human and animal healthy tissues (Krishna *et al.*, 1987; Ember *et al.*, 1995; Ridder *et al.*, 1998; Codrington *et al.*, 2004). Murata *et al.*, (2004) reported that CP and its metabolites induce oxidative stress and react with electron rich areas such as nucleic acids and proteins. Therefore, CP causes disruption of cell growth, mitotic

activity, and functions via alkylation of DNA at the N7 position of guanine. Chromosomal aberrations are due to DNA damage caused by phosphoramidate mustard which leads to break down of the DNA strand (Sharma *et al.*, 2012). The present study demonstrated that the treatment of rats with a single dose of cyclophosphamide caused DNA damage in liver and kidney tissues, as well as decline in mitotic index and increase in the frequency of the chromosomal aberrations in bone marrow cells, these results of the present study are in agreement with all previous studies.

Numerous studies such as (Murata *et al.*, 2004; Abdella, 2008; Sowjanya *et al.*, 2009; Popov *et al.*, 2011; Sharma *et al.*, 2012; Ch and Devi, 2015; Sharma and Agrawa, 2015; Kour *et al.*, 2017) found that Bone marrow analysis technique of rat revealed clear signs of

genotoxicity. Several changes in DNA damage, chromosomal aberrations, Sister Chromatid Exchanges, and decrease in mitotic index after intraperitoneal injection of cyclophosphamide. These reports are in agreement with present study that revealed DNA damage and decrease in the DNA bands, decline in the mitotic index, and the occurrence of chromosomal aberrations such as fragmentation, chromosomal ring, chromatid deletions, and dicentric chromosomes in the treated group with CP only. Abdella (2012) reported that despite that most chemotherapy include CP and are necessary for killing cancer cells, they have undesirable toxicity to normal tissues, where CP treatment has the ability to produce chromosome aberrations and decline in mitotic index in animals, current search results may be involved in solving this problem.

Over all, Cyclophosphamide belong to a class of drugs known as alkylating agent, which have been used to treat some kind of cancer, several studies confirmed that it is a potent anticancer drug but it also affects normal cell division by decreasing the immune responses. The present results indicated that albino rats treated with single dose of CP and left for 45 days showed several times increase in frequency of chromosome aberrations and decrease in the mitotic index. This results are in agreement with the previous investigations which confirmed that CP had the side effects as oxidation and genotoxic effects in normal tissues of treated animals. Therefore, the developing of anti-cancer drug or manufacturing new drugs with low or no side effects has become an important aim in modern studies to overcome chemotherapeutic side effects.

Zinc is a component of chromatin structure, integral in DNA replication and transcription. Thus, zinc is involved in protecting cell and its components against oxidative material and

preserving DNA, regulation of transcription, and replication of DNA through zinc finger proteins (Pavletich *et al.*, 1993; Falchuk, 1998; Dong *et al.*, 1999; Ho, 2003; Emily, *et al.*, 2004; Witkiewicz-Kucharczyk and Bal, 2006; Song *et al.*, 2009; Dhawan and Chadha, 2010). Many studies reported that zinc salts have the ability defend against oxidative harm to the different tissues (Sunderman, 1995; Bagchi *et al.*, 1998; Zago and Oteiza, 2001; Badkoobeh *et al.*, 2013).

Other studies reported that Zn supplementation in rats reduced and ameliorated various types of CP-induced DNA damage (Ishida, 2017; Torabi *et al.*, 2017), and inhibit apoptosis induced by chemotherapeutic agents (Maremanda *et al.*, 2014; Ghobadi *et al.*, 2017). In the present study, doses of (4 mg /kg b. w.) of zinc chloride simultaneous and pretreatment associated with cyclophosphamide exposure, clearly reduced DNA damage, chromosomal aberrations, and elevated of mitotic index. These results indicate zinc chloride has provided protection against cyclophosphamide induced cytotoxicity using various cell lines *in vivo* assay that are in agreement with the previous findings. (Garufi *et al.*, 2015) reported ZnCl₂ could be a valuable element in chemotherapeutic against cancer and reduce the side effects of these drugs. This reports also are agree with the obtained results of the present study that showed DNA fragments, mitotic index, and chromosomal aberrations together indicate the best protective effect of zinc chloride especially in pretreatment against CP induced genotoxicity in rat tissues.

CONCLUSION:

The present data indicated that the pretreatment by zinc chloride or simultaneous treatment have good antimutagenic activity against cyclophosphamide induced genotoxicity, zinc being antioxidant or acting on DNA

replication, resulting in increase in DNA fragments, significant inhibition in the formation of chromosomal aberrations, and elevation in mitotic index that induced by the treatment with cyclophosphamide. Furthermore, pre-treatment with zinc chloride showed more protective effects in all tested rat tissues (liver, kidney, and bon marrow) as well as elevation in mitotic index than simultaneous treatment compared to the treatment with cyclophosphamide alone. The present results have demonstrated

the capability of zinc chloride, as an essential element in the healthy body, and its ability to maintain the normality of DNA fragment and the bone marrow cells in cyclophosphamide-treated rat tissues. Over all, it appears that $ZnCl_2$ is a potential antioxidant as an additive to chemotherapeutic drugs that are toxic to human organs. Present findings indicate favorable prospects for clinical applications for zinc chloride in combination with chemotherapeutic agents like CP.




Fig. 1. PCR products of genomic DNA from liver of tested rat with five ISSR primers. Lane (1) control liver, lane (2) rat liver injected intraperitoneally with a single dose of CP (200 mg/kg b. w.), lane (3) injected intraperitoneally with a single dose of CP (200 mg/kg b. w.) and simultaneously injected intraperitoneally with $ZnCl_2$ (4 mg/kg b.w.), lane (4) rat liver pretreated with $ZnCl_2$ (4 mg/kg b.w.) for 20 days, then injected intraperitoneally with a single dose of CP (200 mg/kg b. w.) and M is DNA Marker.




Fig. 2. PCR products of genomic DNA from kidney of tested rat with five ISSR primers. Lane (1) control kidney, lane (2) rat kidney injected intraperitoneally with a single dose of CP (200 mg/kg b. w.), lane (3) injected intraperitoneally with a single dose of CP (200 mg/kg b. w.) and simultaneously injected intraperitoneally with $ZnCl_2$ (4 mg/kg b.w.), lane (4) rat kidney pretreated with $ZnCl_2$ (4 mg/kg b.w.) for 20 days, then injected intraperitoneally with a single dose of CP (200 mg/kg b. w.) and M is DNA Marker.




Fig. 3. Metaphase figures of chromosomal aberration of bone marrow cells induced by cyclophosphamid treatment showing: (a) normal metaphase and (i) polyploidy chromosomes; the letters (R), (D), (EE), (Dc) and (F) refer to chromosomal ring, chromatid deletion, end to end, dicentric chromosome and chromosomes fragment respectively.




Fig. 4. Dendrogram demonstrating the relationships among tested rat groups and control group in liver and kidney tissues. (L and K) refer to liver and kidney and 1, 2, 3 and 4 refer to group 1, group 2, group 3 and group 4 respectively.

REFERENCES

- Abdella E. (2008). Bacterial lipopolysaccharides pretreatment protects against mutagenic and immunosuppressor effects of cyclophosphamide in mice. *Iran J Cancer Prev.* 4 (1): 155–65.
- Badkoobeh P, Parivar K, Kalantar SM, Hosseini SD and Salabat A. (2013). Effect of nano-zinc oxide on doxorubicin-induced oxidative stress and sperm disorders in adult male Wistar rats. *Iran J. reprod. Med.* V. 11 (5): 355–364.
- Ch S and Devi KR. (2015). Antigenotoxic effects of Aegle marmelos Fruit Extract in Cyclophosphamide Induced Chromosomal Aberrations and Aberrant Sperms in Germ Cells of Swiss Albino Mice. *Int. J. Pure App. Biosci.* 3 (5):178-183.
- Codrington AM, Hales BF, Robaire B. ((2004). Spermogenic Germ Cell Phase-Specific DNA Damage Following Cyclophosphamide Exposure. *Journal of Andrology.* 25 (3): 354–62.
- Dhawan DK. and Chadha VD. (2010). Zinc: A promising agent in dietary chemoprevention of cancer. *Indian J Med Res.* 132 (6): 676–682.
- Dong J, Park JS and Lee SH. (1999). In vitro analysis of the zinc-finger motif in human replication protein A. *Biochem J.* 337: 311–7.
- Ebisch IMW, Thomas CMG, Peters WHM, Braat DDM and Steegers-Theunissen RPM. (2007). The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. *Hum Reprod Update.* 13: 163–174.
- Ember I, Raposa T, Vargo C, Hecceg L and Kiss I. (1995). Carcinogenic effects of cytostatic protocols in CBA/Ca mice *In Vivo.* 9, 65-69.

- Estibaliz L, Fernánde Z, Anne-Lee G, Andersson M, Hellman B` and Dencker L. (2003). Cadmium-Induced Changes in Apoptotic Gene Expression Levels and DNA Damage in Mouse Embryos Are Blocked by Zinc. *Toxicological Sciences* 76, 162–170.
- Falchuk KH. (1998). The molecular basis for the role of zinc in developmental biology. *Mol. Cell. Biochem.*, 188, pp. 41-48.
- Garufi A, Ubertini V, Mancini F, D’Orazi V, Baldari S, Moretti F, Bossi G and D’Orazi G. (2015). The beneficial effect of Zinc (II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells. *J. exp. Clin. Cancer res.* 34 (1): 87.
- Grüngreiff K. (2016). Zinc Deficiency and Liver Diseases- General Observations. *SM J Hepat Res Treat.* 2 (1): 1008.
- Ghobadi E, Moloudizargari M, Asghari MH, Abdollahi M. (2017). The mechanisms of cyclophosphamide-induced testicular toxicity and the protective agents. *Exp Opin Drug Metab Toxicol.* 13:525–536.
- Haubitz, M. (2007). Acute and long-term toxicity of Cyclophosphamide. *Tx Med.*, 19: 26-31.
- Ho E, Courtemanche C, Ames BN. (2003). Zinc deficiency induces oxidative DNA damage and increases p53 expression in human lung fibroblasts. *J Nutr.* 133: 2543–8.
- Ho E. (2004). Zinc deficiency, DNA damage and cancer risk. *The journal of Nutritional Biochemistry.* Volume 15, Issue 10, PP 572-578.
- Ishida T. (2017). Anti-Cancer Effects of Zinc (II) Ion in Tumor Formation and Growth, Proliferation, Metastasis and DNA Damage. *Degenerative Intellectual & Developmental Disabilities* 1(1): 1-7.
- Krishna G, Nath J, Peterson M and Ong T. (1987). Cyclophosphamide-induced cytogenetic effects in mouse bone marrow and spleen cells in vivo and in vivo/in vitro assays. *Teratog Carcinog Mutagen* 7:183-195.
- Kruawanand K and Kangsadalampai K. (2006). Antioxidant activity, phenolic compound contents and antimutagenic activity of some water extract of herbs. *Thai J. Pharm. Sci.*, 30: 28-35.
- Koura J, Ali NMd, Ganaiea HA and Tabassum N. (2017). Amelioration of the cyclophosphamide induced genotoxic damage in mice by the ethanolic extract of *Equisetum arvense*. *Toxicology reports.* Vol. 4, PP 226-233.
- Leoni G, Rosato A and Perozzi G. (2014). Zinc proteome interaction network as a model to identify nutrient-affected pathways in human pathologies. *Genes Nutr.* 9: 436.
- Levine AJ. (1997). p53, the cellular gatekeeper for growth and division *Cell*, 88, pp. 323-331.
- Lindahl M, Leanderson P, Tagesson C. (1998). Novel aspects on metal fume fever: Zinc stimulates oxygen radical formation in human neutrophils. *Hum Exp Toxicol.* 17: 105–110.
- Maremanda KP, Khan S and Jena G. (2014). Zinc protects cyclophosphamide-induced testicular damage in rat: Involvement of metallothionein, tesmin and Nrf2. *Biochemical and Biophysical Communications.* Volume 445, Issue 3, Pp. 591-596.

- Murata M, Suzuki T, Midorikawa K, Oikawa S, Kawanishi S. (2004). Oxidative DNA damage induced by a hydroperoxide derivative of cyclophosphamide. *Free Radical Biology and Medicine* . 37(6):793–802.
- Noh KM. and Koh JY. (2000). Induction and activation by zinc of nadph oxidase in cultured cortical neurons and astrocytes. *J Neurochem.* 75: 1878–1888.
- Rehman MU.; Tahir M.; Ali F.(2012). Cyclophosphamide-induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of Ellagic acid *Mol. Cell. Biochem.*, 365 pp. 119-127.
- Ridder D, de Poppel H, Van and Demonty L. (1998). Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. *J. Urol.* 159, 1881- 1884.
- Pavletich NP, Chambers KA and Pabo CO. (1993). The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. *Genes Dev.* 7: 2556–4.
- Prasad AS. (2003). Zinc deficiency. *BMJ*, 326, pp. 409-410.
- Popov B, Georgieva Sv and Gadjeva V. (2011). Modulatory effects of total extract of *Haberlea rhodopensis* against the cyclophosphamide induced genotoxicity in rabbit lymphocytes *in vivo*. *Trakia Journal of Sciences*, Vol. 9, No 1, pp 51-57.
- Powell SR. (2000). Zinc and Health: Current Status and Future Directions, the Antioxidant Properties of Zinc. *Nutr.* 130:1447S–1454S.
- Sandstrom P.A., Mannie M.D. and Buttke T.M. (1994). Inhibition of activation induced death in T cell hybridomas by thiol antioxidants: oxidative stress as a mediator of apoptosis. *J Leukoc Biol.* 55: 221–226.
- Satoh M, Kondo Y, Mita M, Nakagawa I, Naganuma A and Imura N. (1993). Prevention of carcinogenicity of anticancer drugs by metallothionein induction. *Cancer Res.* 53: 4767–4768.
- Sharaf-Eldeen K, El-Ezabi M, and El-Bohaissi A. (2006). The molecular changes of hepatocytes in *Tilapia zillii* under the Effect of the agricultural and industrial pollution in River Nile. *Egypt. J. Auqat. Biol. and Fish.* 10 (2). 55-77.
- Sharma S, Sharma G and Mehta A. (2012). Antimutagenicity protection of *Ficus benghalensis* extract against cyclophosphamide genotoxicity in rat bon marrow. *Asian J Pharm Clin Res*, Vol 5, Suppl 2, 27-29.
- Sharma V and Agrawal RC. (2015). Evaluation of Anticlastogenic effects of *Glycyrrhiza glabra* root extract against Cyclophosphamide induced Chromosomal aberration in Swiss albino Mice. *Journal of Applied Pharmaceutical Science* Vol. 5 (06), pp. 127-132.
- Singh P and Sankhla V. (2010). In situ protective effect of curcumin on cadmium chloride induced genotoxicity in bone marrow chromosomes of Swiss albino mice. *Journal of Cell and Molecular Biology* 8(2): 57-64.
- Song Y, Leonard SW., Traber MG. and Ho E. (2009). Zinc Deficiency Affects DNA Damage, Oxidative Stress, Antioxidant Defenses, and DNA Repair in Rats. *J Nutr.*; 139 (9): 1626–1631.

- Sowjanya L, Devi RK and Madhavi D. (2009). Modulatory effects of garlic extract against the cyclophosphamide induced genotoxicity in human lymphocytes in vitro. *Journal of Environmental Biology*. 30 (5) 663-666.
- Sunderman FW. (1995). The influence of zinc on apoptosis. *Ann Clin Lab Sci*. 25:134.
- Sundramoorthy KPK, Sathiyavedu TS. and Rabandi R. (2004). Interactive effects of saffron with garlic and curcumin against cyclophosphamide induced genotoxicity in mice. *Asia Pac. J. ClinNutr*. 13: 292-294.
- Sushma Ch and Devi KR. (2015). Antigenotoxic effects of Aegle marmelos Fruit Extract in Cyclophosphamide Induced Chromosomal Aberrations and Aberrant Sperms in Germ Cells of Swiss Albino Mice. *Int. J. Pure App. Biosci*. 3 (5): 178-183.
- Torabi F, Shafaroudi MM and Rezaei N. (2017). Combined protective effect of zinc oxide nanoparticles and melatonin on cyclophosphamide-induced toxicity in testicular histology and sperm parameters in adult Wistar rats. *Int J Reprod Biomed (Yazd)*. 15 (7): 403-412.
- Witkiewicz-Kucharczyk A and Bal W. (2006). Damage of zinc fingers in DNA repair proteins, a novel molecular mechanism in carcinogenesis. *Toxicol Lett*. 162: 29-42.
- Yosida TH., Truchiya K, Moriwaki K. (1977). Frequency of chromosome polymorphism of *Rattus rattus* collected in Japan. *Chromosoma* 33: 30-40.
- Zago MP and Oteiza PI. (2001). The antioxidant properties of zinc: interactions with iron and antioxidants. *Free Radic Biol Med*. 31: 266-274.
- Zietkiewicz E, Rafalski A and Labuda D. (1994). Genome fingerprinting by simple sequence repeat (SSR)-anchored polymerase chain reaction amplification. *Genomics*, 20: 176-183.

ARABIC SUMMARY

التأثيرات الوقائية لكلوريد الزنك على السمية الجينية الناتجة من السيكلوفوسفاميد في أنسجة الجرذان البيضاء في الجسم الحي

فايزة محمد علي

1- قسم الحيوان - كلية العلوم - جامعة جنوب الوادي - قنا 83523 - مصر

السيكلوفوسفاميد (Cyclophosphamide) هو أحد العقاقير الشائعة الاستعمال في علاج العديد من أنواع الأورام السرطانية واختلالات المناعة الذاتية. وهو يمثل جزء من أدوية العلاج الكيميائي للسرطان، ويصنف ضمن الأدوية ذات التأثير المباشر على البنية الجزيئية للحمض النووي (DNA) للخلايا السرطانية. فهو ينتمي لمستحضرات فئة عوامل الألكلة (Alkylation agents) التي تصيف مجموعة ألكيل (Alkyl) إلى الدنا مما يمنع عملية مضاعفة الحمض النووي و تكاثر الخلايا السرطانية، حيث يقوم بتكسير هيكل الحمض النووي في كل مراحل دورة حياة الخلية السرطانية، بما يوقف نموها و يتسبب في موتها.

ومن المعروف أن الزنك هو احد المعادن الأساسية التي تساهم في تكوين عدد كبير من الإنزيمات وعوامل النسخ ويدخل في تركيب جميع أنسجة الجسم. وقد اثبتت الأبحاث العملية أن الزنك له تأثير مضاد للإجهاد التأكسدي ويلعب دور هام في نسخ وتكرار وإصلاح الدنا (DNA) حيث أن بروتينات أصابع الزنك (zinc finger proteins) تنظم عمليات النسخ والتكرار وإصلاح الضرر في الدنا (DNA). لذا فهو له دور هام في حماية الخلايا ومحتوياتها.

وقد كان الهدف من هذه الدراسة إلقاء الضوء على التأثير العلاجي والوقائي لكلوريد الزنك ضد الآثار الجانبية المترتبة على استعمال عقار السيكلوفوسفاميد في بعض العلاجات الدوائية لبعض الأمراض. وتناولت الدراسة التقنيات التالية:

1- تقنية (Inter Simple Sequence Repeat ISSR) باستخلاص الدنا من نسيج الكبد والكلى لذكور الجرذان البيضاء باعتبارها من الاعضاء التي تتأثر من جراء المعالجة بعقار السيكلوفوسفاميد
2- اعداد التحضيرات الكروموسومية للانقسام الميوزي لخلايا نخاع العظام لتحديد انحرافات الكروموسومات في الاتجاهين التركيبي والعددي (Chromosomal aberrations) وتقييم مؤشر الانقسام للخلية (mitotic index).

ولقد تم تصميم تلك الدراسة باستخدام عدد 24 من ذكور الجرذان البيضاء، تم تقسيمهم إلى أربعة مجموعات بكل مجموعة 6 جرذان.

المجموعة الأولى: تعتبر المجموعة الضابطة وقد تم حقنها في الغشاء البريتوني بمحلول ملحي فسيولوجي بجرعة (1 مللتر/كجم) من وزن الجسم كل يوم بعد يوم لمدة عشرون يوماً.
المجموعة الثانية: تعتبر المجموعة المعالجة بعقار السيكلوفوسفاميد وقد تم حقنها خلال الغشاء البريتوني بجرعة واحدة من السيكلوفوسفاميد (٢٠٠ مجم/كجم من وزن الجسم) ثم تركت لمدة خمسة واربعون يوماً.
المجموعة الثالثة: تعتبر المجموعة المعالجة بالسيكلوفوسفاميد وكلوريد الزنك، وقد تم حقنها بجرعة واحدة من السيكلوفوسفاميد (٢٠٠ مجم/كجم من وزن الجسم) وفي نفس الوقت بدأ حقنها بمادة كلوريد الزنك خلال الغشاء البريتوني بجرعة (٤ مجم/كجم من وزن الجسم) كل يوم بعد يوم لمدة عشرون يوماً.
المجموعة الرابعة: وتعتبر المجموعة الوقائية حيث تم حقنها بمادة كلوريد الزنك (٤مجم/كجم من وزن الجسم) كل يوم بعد يوم لمدة عشرون يوماً قبل حقنها بعقار السيكلوفوسفاميد. وقد تم حقنها بالسيكلوفوسفاميد في اليوم الحادي والعشرون بجرعة واحدة (٢٠٠ مجم/كجم من وزن الجسم) ثم تركت لمدة 45 يوماً.

بعد 45 يوماً من الحقن بالسيكلوفوسفاميد للمجموعات الثلاث، تم اجراء الفحوصات والتحليل وقد اظهرت الدراسة بتقنية (ISSR) ان المجموعة المعالجة بعقار السيكلوفوسفاميد (مجموعة 2) حدث بها تحلل للدنا (DNA) في خلايا الكبد والكلى وكذلك وجدت اختلافات معنوية في عدد الكروموسومات الشاذة ونوعيتها في التحضيرات الكروموسومية لنخاع العظام وانخفاض واضح في مؤشر الانقسام مقارنة بالمجموعة الضابطة. وبمقارنة نتائج المجموعة المعالجة بعقار السيكلوفوسفاميد بالمجموعتين المعالجتين بكلوريد الزنك المتزامن مع العلاج بعقار السيكلوفوسفاميد (مجموعة 3) أو المعطى قبل العلاج بالسيكلوفوسفاميد (مجموعة 4) وجد تحسناً واضحاً في الدنا ظهر في زيادة عدد جزم الدنا الناتجة وكذلك انخفاض في انحرافات الكروموسومات الشاذة وارتفاع في مؤشر الانقسام.

وقد خلصت الباحثة إلى أن كلوريد الزنك المتزامن في العلاج مع السيكلوفوسفاميد والمعطى مسبقاً قبل العلاج بالسيكلوفوسفاميد له نشاط مضاد للطفرات الجينية في انسجة الجرذان.
وأن العلاج بكلوريد الزنك قبل البدء في العلاج بالسيكلوفوسفاميد له تأثير أكثر فاعلية على السمية الجينية للسيكلوفوسفاميد مقارنة بالعلاج بكلوريد الزنك المتزامن مع العلاج بالسيكلوفوسفاميد.
ونستخلص من هذه الدراسة أن كلوريد الزنك ينبغي أن يستخدم في توليفة علاجية مع العلاج بالسيكلوفوسفاميد كعلاج وقائي قبل العلاج بالسيكلوفوسفاميد للمرضى الذين تتطلب حالاتهم ضرورة العلاج بالسيكلوفوسفاميد.